After last year’s flop of Prothena’s NEOD001, Takeda’s Ninlaro fails to treat the underlying cause of the non-genetic form of this disease.
Celgene had many fingers in many pies – so what will happen now to its smaller collaborators?
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.
Pharma companies have passed on in-licensing drugs such as Kite Pharma’s CAR-T therapy and Incyte’s IDO inhibitor. Do they know something?